AstraZeneca Reports P-III (DELIVER) Trial Results of Farxiga (dapagliflozin) for Heart Failure
Shots:
- The P-III (DELIVER) trial evaluates Farxiga vs PBO in 6263 patients with HF with LVEF ≥40% with/out T2D & mildly reduced or preserved EF
- The results showed an 18% vs 19.5% reduction in the composite outcome of CV death or worsening of HF with absolute risk reduction (3.1%) over a median follow-up of 2.3yrs. along with symptom benefits in PROs. Each individual component enhanced the superiority of the 1EPs
- The safety & tolerability profiles were consistent with the well-established safety profile of Farxiga. The results were presented at ESC 2022 & published in the NEJM. The results complement the most recent treatment recommendations, advocating an earlier start of medical treatment. They may also promote broader use of SGLT2 inhibitors in clinical settings
Ref: Businesswire | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
